Business Description
Kuros Biosciences Ltd
ISIN : CH0325814116
Compare
Compare
Traded in other countries / regions
KURN.SwitzerlandKURNz.UKCSBTF.USAYTSN.Germany IPO Date
2013-05-17Description
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.27 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 24.72 | |||||
| Beneish M-Score | -2.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 76.8 | |||||
| 3-Year EBITDA Growth Rate | 6.9 | |||||
| 3-Year EPS without NRI Growth Rate | 6.8 | |||||
| 3-Year FCF Growth Rate | 13.6 | |||||
| 3-Year Book Growth Rate | -15.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.93 | |||||
| 9-Day RSI | 69.91 | |||||
| 14-Day RSI | 69.36 | |||||
| 6-1 Month Momentum % | 120.19 | |||||
| 12-1 Month Momentum % | 504.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | |||||
| Quick Ratio | 2.17 | |||||
| Cash Ratio | 1.17 | |||||
| Days Inventory | 178.65 | |||||
| Days Sales Outstanding | 45.68 | |||||
| Days Payable | 58.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -0.08 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.14 | |||||
| Operating Margin % | -17.55 | |||||
| Net Margin % | -16.91 | |||||
| FCF Margin % | -6.21 | |||||
| ROE % | -14.74 | |||||
| ROA % | -11.74 | |||||
| ROIC % | -18.69 | |||||
| 3-Year ROIIC % | 27.95 | |||||
| ROC (Joel Greenblatt) % | -162.58 | |||||
| ROCE % | -12.32 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.64 | |||||
| PB Ratio | 11.01 | |||||
| Price-to-Tangible-Book | 33.92 | |||||
| EV-to-EBIT | -83.25 | |||||
| EV-to-EBITDA | -125.34 | |||||
| EV-to-Revenue | 12.35 | |||||
| EV-to-FCF | -188 | |||||
| Price-to-Median-PS-Value | 1.48 | |||||
| Price-to-Net-Current-Asset-Value | 40.09 | |||||
| Earnings Yield (Greenblatt) % | -1.2 | |||||
| FCF Yield % | -0.49 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers